• 1
    WHO. Hepatitis C. Available at: Accessed March 4, 2009.
  • 2
    Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(Suppl. 1): 218.
  • 3
    Koretz RL. Decisions, decisions, decisions. Gastroenterology 2000; 118: 126870.
  • 4
    Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36(Suppl. 1): 13545.
  • 5
    Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 22530.
  • 6
    Consensus Statement. EASL International consensus conference on hepatitis C. J Hepatol 1999; 30: 95661.
  • 7
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 242941.
  • 8
    Koretz RL, Gluud C. Prolonged therapy for hepatitis C with low-dose peginterferon. N Engl J Med 2009; 360: 1151.
  • 9
    Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007; 46: 73442.
  • 10
    Gluud LL, Gluud C. Meta-analyses on viral hepatitis. Infect Dis Clin North Am 2009; 23: 31530.
  • 11
    Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2005; 165: 220612.
  • 12
    Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev 2010; 1: CD005445.
  • 13
    Gluud C, Nikolova D, Klingenberg SL, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration: Cochrane Review Groups (CRGs). Cochrane Library 2010; 2: LIVER.
  • 14
    Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Br Med J 2008; 336: 6015.
  • 15
    Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 24854.
  • 16
    Berkey CS, Mosteller F, Lau J, Antman EM. Uncertainty of the time of first significance in random effects cumulative meta-analysis. Control Clin Trial 1996; 17: 35771.
  • 17
    Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 6475.
  • 18
    Thorlund K, Devereaux PJ, Wetterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 2009; 38: 27686.
  • 19
    Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008; 61: 7639.
  • 20
    Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive – trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 2009; 38: 28798.
  • 21
    Afshari A, Wetterslev J, Brok J, Møller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Br Med J 2007; 335: 124851.
  • 22
    Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomized controlled trials. Br Med J 2005; 331: 31321.
  • 23
    RevMan. Review Manager (RevMan), Version 5.0 for Windows. Copenhagen: The Nordic Cochrane Center, 2008.
  • 24
    Thorlund K, Engstrøm J, Wetterslev J, et al. Trial Sequential Analysis, Version 0.8 [Computer Program]. Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, 2008.
  • 25
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trial 1986; 7: 17788.
  • 26
    Myers RP, Regimbeau C, Thevenot T, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev 2002; 2: CD000370.
  • 27
    National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 – June 10–12, 2002. Hepatology 2002; 36(Suppl. 1): S320.
  • 28
    Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 29
    Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 183950.
  • 30
    Bucher HC, Guyatt GH, Cook DJ, Holbrook A. Users’ guides to the medical literature XIX. Applying clinical trial results. A: How to use an article measuring the effect of an intervention on surrogate end points. JAMA 1999; 282: 77180.